There is an increased risk of allergic reactions, including anaphylaxis, in patients previously exposed to platinum therapy. Contraindicated in patients with severe bone marrow depression or significant bleeding. Patients with poor performance status have a higher incidence of severe leukopenia and thrombocytopenia. Lengthening duration of single IV administration to 24 h or dividing total dose over 5 consecutive daily pulse doses may reduce emesis. Similar compounds shown to be carcinogenic.
Drug is mutagenic in vivo and in vitro.
Reactions reported in 1,893 patients with various tumors given drug as single-agent therapy. The information provided above is based on the manufacturer's official US labeling for this product, last updated May 2000. Inc. All rights reserved.